CAR T-Cell Therapy: Optimal Management of AEs

home / video-series / car-t-cell-therapy-optimal-management-of-aes
Bijal Shah, MD, MS

EP. 1: Dr. Shah and Dr. Wang on CAR T-Cell Therapy–Associated Toxicities in Hematologic Malignancies

Bijal Shah, MD, Moffit Cancer Center;Michael L. Wang, MD University of Texas MD Anderson Cancer Center
November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the main CAR T-cell therapy–associated toxicities in hematologic malignancies.

Watch

Michael Wang, MD

EP. 2: Dr. Shah and Dr. Wang on Managing CRS and Neurotoxicity in Leukemia/Lymphoma

Bijal Shah, MD, Moffit Cancer Center;Michael L. Wang, MD University of Texas MD Anderson Cancer Center
November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss management strategies for CAR T-cell therapy–related cytokine release syndrome and neurotoxicity in leukemia and lymphoma.

Watch

Bijal Shah, MD, MS

EP. 3: Dr. Shah and Dr. Wang on Navigating the Referral Process for CAR T-Cell Therapy in Hematologic Malignancies

Bijal Shah, MD, Moffit Cancer Center;Michael L. Wang, MD University of Texas MD Anderson Cancer Center
November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss navigating the referral process for CAR T-cell therapy in hematologic malignancies.

Watch

Michael Wang, MD

EP. 4: Dr. Shah and Dr. Wang on the Challenges of Managing High-Risk MCL

Bijal Shah, MD, Moffit Cancer Center;Michael L. Wang, MD University of Texas MD Anderson Cancer Center
November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the challenges of managing high-risk mantle cell lymphoma.

Watch

Bijal Shah, MD, MS

EP. 5: Dr. Shah and Dr. Wang on the Need for Academic and Community Collaboration With CAR T-Cell Therapy

Bijal Shah, MD, Moffit Cancer Center;Michael L. Wang, MD University of Texas MD Anderson Cancer Center
November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.

Watch

Dr. Hill and Dr. Sauter Address Financial Toxicity in CAR T-Cell Therapy

EP. 6: Dr. Hill and Dr. Sauter Address Financial Toxicity in CAR T-Cell Therapy

Craig Sauter, MD;Brian Hill, MD, PhD, Cleveland Clinic
November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, address the issue of financial toxicity in CAR T-cell therapy.

Watch

Cleveland Clinic Experts Discuss the Potential for Allogeneic CAR T-Cell Agents

EP. 7: Cleveland Clinic Experts Discuss the Potential for Allogeneic CAR T-Cell Agents

Craig Sauter, MD;Brian Hill, MD, PhD, Cleveland Clinic
November 2nd 2022

Brian T. Hill, MD, PhD, and Craig Sauter, MD, discuss the promise of allogeneic CAR T-cell products.

Watch

Dr. Hill and Dr. Sauter Discuss the Future of CAR T-Cell Products Agents in Lymphoma

EP. 8: Dr. Hill and Dr. Sauter Discuss the Future of CAR T-Cell Products Agents in Lymphoma

Craig Sauter, MD;Brian Hill, MD, PhD, Cleveland Clinic
November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss potential directions for CAR T-cell therapy in lymphomas.

Watch

Cleveland Clinic Experts Assess Strategies to Accelerate CAR T-Cell Production

EP. 9: Cleveland Clinic Experts Assess Strategies to Accelerate CAR T-Cell Production

Craig Sauter, MD;Brian Hill, MD, PhD, Cleveland Clinic
November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss recent data showing that the CAR T-cell production can be shortened.

Watch

Dr. Hill and Dr. Sauter Consider CAR T-Cell Therapy in Second-Line Setting for DLBCL

EP. 10: Dr. Hill and Dr. Sauter Consider CAR T-Cell Therapy in Second-Line Setting for DLBCL

Craig Sauter, MD;Brian Hill, MD, PhD, Cleveland Clinic
November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.

Watch